Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?  by Sabloff, Mitchell et al.
Biol Blood Marrow Transplant 20 (2014) 421-434American Society for Blood
ASBMT
and Marrow TransplantationBrief Articles
Does Total Body Irradiation Conditioning Improve
Outcomes of Myeloablative Human Leukocyte
AntigeneIdentical Sibling Transplantations for
Chronic Lymphocytic Leukemia?
Mitchell Sabloff 1,*, Ronald M. Sobecks 2, Kwang Woo Ahn 3, Xiaochun Zhu 4,
Marcos de Lima 5, Jennifer R. Brown 6, Yoshihiro Inamoto 7, H. Kent Holland 8,
Mahmoud D. Aljurf 9, Mary J. Laughlin 10, Rammurti T. Kamble 11,
Jack W. Hsu 12, Baldeep M. Wirk 13, Matthew Seftel 14, Ian D. Lewis 15,
Mukta Arora 16, Edwin P. Alyea 6, Matt E. Kalaycio 2, Jorge Cortes 17,
Richard T. Maziarz 18, Robert Peter Gale 19, Wael Saber 4
1Division of Hematology, Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa,
Ontario, Canada
2Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, Ohio
3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin
4Center for International Blood & Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, Wisconsin
5Division of Hematologic Malignancies and Stem Cell Transplantation, Seidman Cancer Center, University Hospitals Case Medical
Center, Cleveland, Ohio
6Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts
7Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
8Division of Oncology and Hematology, The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia
9Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia
10Hematopoietic Cell Transplantation Program, University Hospitals Case Medical Center, University of Virginia Health System,
Charlottesville, Virginia
11Division of Hematology and Oncology, Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas
12Division of Hematology and Oncology, Department of Medicine, Shands Healthcare & University of Florida, Gainesville, Florida
13Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York
14Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
16Division of Hematology, Oncology and Transplant, University of Minnesota Medical Center, Fairview, Minneapolis, Minneapolis
17Department of Leukemia, MD Anderson Cancer Center, Houston, Texas
18Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon
19 Section of Hematology, Division of Experimental Medicine, Department of Medicine, Imperial College, London, United KingdomArticle history:
Received 16 September 2013
Accepted 29 November 2013
Key Words:
Chronic lymphocytic leukemia
Total body irradiation
Conditioning
MyeloablativeFinancial disclosure: See Acknowle
* Correspondence and reprint r
Division of Hematology, Departme
The Ottawa Hospital Research Inst
Canada K1H 8L6.
E-mail address: msabloff@ottaw
1083-8791/$ e see front matter 
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
An allogeneic hematopoietic cell transplantation from an HLA-identical donor after high-dose (myeloablative)
pretransplantation conditioning is an effective therapy for some people with chronic lymphocytic leukemia
(CLL). Because CLL is a highly radiosensitive cancer, we hypothesized that total body irradiation (TBI) con-
ditioning regimens may be associated with better outcomes than those without TBI. To answer this, we
analyzed data from 180 subjects with CLL receiving myeloablative doses of TBI (n ¼ 126) or not (n ¼ 54), who
received transplants from an HLA-identical sibling donor between 1995 and 2007 and reported to the Center
for International Blood & Marrow Transplant Research. At 5 years, treatment-related mortality was 48% (95%
conﬁdence interval [CI], 39% to 57%) versus 50% (95% CI, 36% to 64%); P ¼ NS. Relapse rates were 17% (95% CI,
11% to 25%) versus 22% (95% CI, 11% to 35%); P ¼ NS. Five-year progression-free survival and overall survival
were 34% (95% CI, 26% to 43%) versus 28% (95% CI, 15% to 42%); P ¼ NS and 42% (95% CI, 33% to 51%) versus 33%
(95% CI, 19% to 48%); P ¼ NS, respectively. The single most common cause of death in both cohorts was
recurrent/progressive CLL. No variable tested in the multivariate analysis was found to signiﬁcantly affect
these outcomes, including having failed ﬂudarabine. Within the limitations of this study, we found no dif-
ference in HLA-identical sibling transplantation outcomes between myeloablative TBI and chemotherapy
pretransplantation conditioning in persons with CLL.
 2014 American Society for Blood and Marrow Transplantation.dgments on page 424.
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13.11.032INTRODUCTION
Hematopoietic cell transplantation from a human leuko-
cyte antigen (HLA)-identical sibling is an effective therapy for
selected persons with chronic lymphocytic leukemia (CLL)
[1-8]. Myeloablative conditioning regimens, with or without
total body irradiation (TBI), were commonly used in the past.
Although reduced-intensity regimens are increasingly used,
Table 1
Subject-, Disease- and Transplantation-Related Variables
Variable TBI CT P Value
Subject-related
Subjects, n 126 54
Centers, n 65 24
Age, median (range), yr 48 (24-64) 49 (27-62) .38
Gender
Male 86 41 .30
Karnofsky score before
transplantation
.41
<90% 41 19
90% 81 35
Missing 4 0
Disease-related
Rai stage at diagnosis .19
Early Rai stages 83 29
Late Rai stages 24 11
Missing 19 14
Rai stage before transplantation .46
Early 73 29
Advanced 41 22
Missing 12 3
Constitutional-symptoms at
diagnosis
.63
Absent 76 34
Present 26 8
Unknown 24 12
Elevated LDH at transplantation .69
No 69 26
Yes 37 19
Unknown 20 9
Splenectomy .42
No 115 49
Yes 8 5
Missing 3 0
Lines therapy before
transplantation, median
(range), n
3 (1-5) 3 (1-5) .98
Disease status at transplantation .96
CR/PR/nPR 58 24
Stable/progressive 62 27
Unknown/untreated/not
evaluable
6 3
Refractory to prior therapy .74
No 21 10
Yes 79 36
Unknown/missing 5 1
Fludarabine refractory .80
No 57 23
Yes 57 27
Missing 12 4
Transplantation related
Interval from diagnosis to
transplantation, median
(range), mo
42 (2-223) 41 (4-198) .47
Donor-recipient sex-match .48
M-M 42 25
F-F 13 3
M-F 26 10
F-M 44 16
Missing 1 0
Donor-recipient CMV match .57
D()/R() 31 15
D(þ)/R(þ) 57 25
D(þ)/R() 13 5
D()/R(þ) 24 7
Missing 1 2
Graft source .006
Bone marrow 63 15
Blood 63 39
Donor age, median (range), yr 47 (13-66) 45 (24-67) .70
ATG <.001
Yes 0 8
No 125 46
Missing 1 0
(continued on next page)
Table 1
(continued)
Variable TBI CT P Value
GVHD prophylaxis .24
Tacrolimus þ
methotrexate þ/ other
13 11
Tacrolimus þ/ other 8 5
Cyclosporine þ
methotrexate þ/ other
80 32
Cyclosporine þ/ other 20 4
Missing 5 2
Year of transplantation .02
1995-2000 100 34
2001-2007 26 20
Follow-up of survivors, median
(range), mo
130 (3-175) 56 (3-135)
TBI indicates total body irradiation; CT, chemotherapy; LDH, lactate
hydrogenase; CR, complete remission; PR, partial remission; nPR, nearly
partial remission; M, male; F, female; CMV, cytomegalovirus; ATG, antith-
ymocyte globulin; GVHD, graft-versus-host disease.
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are mature for analysis. Most TBI regimens also contain
cyclophosphamide [9-11]. Myeloablative regimens without
TBI (referred to herein as chemotherapy [CT]) typically
include busulfan, often, but not always, with cyclophospha-
mide [12,13]. Two small retrospective studies comparing
these conditioning regimens showed no difference or
favored a TBI-based conditioning regimen [12,14].
TBI may be especially effective in highly radio-sensitive
cancers, such as CLL [15-17]. Consequently, we hypothesized
that TBI-containing conditioning regimens may have better
outcomes than CT conditioning regimens. We compared
transplantation outcomes of these two conditioning regi-
mens in subjects reported to the Center for International
Blood & Marrow Transplant Research (CIBMTR).
METHODS
Data Sources
The CIBMTR is a combined research program of the Medical College of
Wisconsin and the National Marrow Donor Program. CIBMTR comprises a
voluntary network ofmore than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and autologous trans-
plants to a centralized statistical center. Observational studies conducted by
the CIBMTR are performed in compliance with all applicable federal regu-
lations pertaining to the protection of human research participants. Pro-
tected health information used in the performance of such research is
collected and maintained in CIBMTR’s capacity as a Public Health Authority
under the HIPAA Privacy Rule. Additional details regarding the data source
are described elsewhere [18].
Inclusion Criteria
One hundred eighty patients with CLL (Richter’s transformation and
prolymphocytic leukemia were excluded) who underwent a conventional
myeloablative (no reduced-intensity) allogeneic transplantation from an
HLA-identical sibling between 1995 and 2007 were included. This popu-
lation was extracted from an initially larger cohort of 1260 subjects re-
ported to the CIBMTR. Patients who received unrelated donor transplants
were excluded because of too many missing pieces of data, leaving us with
619 subjects. Further exclusions included subjects with twin and other
related donors (n ¼ 42), cord blood donors (n ¼ 31), subjects with missing
survival data (n ¼ 1), subjects with missing data on regimen intensity
(n ¼ 25), lack of informed consent (n ¼ 68), subjects with ex vivo T cell
depleted grafts (n ¼ 62), and those who received less intensive
conditioning (n ¼ 210). Completeness index was 77% overall with good
follow-up in both cohorts of 91% at 3 years and 84% at 5 years post trans-
plantation [19].
Deﬁnitions of Variables and Outcomes
Rai stage and Karnofsky performance score were categorized as previ-
ously described [20,21]. Constitutional symptoms included unexplained
weight loss of> 10% of bodyweightwithin 6months, fever (>38C), or night
Figure 1. Adjusted survival.
Table 2
Causes of Death
Variable TBI CT
Deaths, n 81 33
Causes
CLL 21 9
GVHD 11 3
ARDS 4 0
Infection 18 3
Organ failure 11 9
Graft failure 2 0
Hemorrhage 2 3
Interstitial pneumonitis 1 0
Other 2 3
Secondary malignancy 4 0
Thromboembolic disease 0 1
Veno-occlusive disease 2 2
Missing 3 0
TBI indicates total body irradiation; CT, chemotherapy; CLL, chronic lym-
phocytic leukemia; GVHD, graft-versus-host disease; ARDS, acute respira-
tory distress syndrome.
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gressive disease after ﬂudarabine-based therapy at any stage of treatment,
as reported by the participating centers. Refractoriness to the prior therapy
was deﬁned as stable or progressive disease after the most recent therapy as
reported by the participating centers. Myeloablative pretransplantation
conditioning regimens are deﬁned according to the CIBMTR Reduced-
Intensity Conditioning Regimen Workshop [22,23].
Endpoints were measured from the time of transplantation. For survival,
subjects were considered to have an event at time of death from any cause.
Survivors were censored at last contact. Relapse was deﬁned by standard
criteria and treatment-related mortality (TRM) was considered a competing
event. TRM was deﬁned as death without leukemia recurrence. Relapse was
considered a competing event. Progression-free survival (PFS) was deﬁned
as time to treatment failure (death or relapse). Overall survival (OS) was
deﬁned as time to death from any cause. For relapse, TRM, and PFS, subjects
alive in continuous complete remission were censored at last follow-up.
Neutrophil recovery was deﬁned as the ﬁrst day of neutrophils  .5  109/
L for 3 consecutive days. Platelet recovery was deﬁned as achieving platelets
> 20  109/L without platelet transfusions for 7 days. Acute and chronic
graft-versus-host disease (GVHD) were graded as described [24,25]. For
engraftment and GVHD, death without the event was considered a
competing event.
Data Analysis
Subject-, disease-, and transplantation-related variables of the TBI and
CT cohorts were compared using the chi-square test for categorical variables
and the Kruskal-Wallis test for continuous variables. TRM, relapse,
engraftment, acute, and chronic GVHD were estimated as cumulative in-
cidences, taking into account competing risks. Probabilities of PFS and
survival were calculated using the Kaplan-Meier estimator with variance
estimated by the Greenwood formula. Survival curve estimates were
compared using the log-rank test. Multivariate analyses were conducted to
identify signiﬁcant predictors of hematopoietic recovery, acute and chronic
GVHD, TRM, relapse, PFS, and OS.
The proportional hazards model was built by forcing the main effect
variable (TBI versus CT) into the model. Backward elimination with a cri-
terion of P < .05 for retentionwas used to select a ﬁnal model. The following
variables were analyzed for their prognostic value on each of the outcomes:
subject-related variables (age, gender, and Karnofsky performance score at
transplantation), disease-related variables (Rai stage at diagnosis, Rai stage
at transplantation, constitutional symptoms at diagnosis, elevated lactate
dehydrogenase at transplantation, splenectomy, refractoriness to ﬂudar-
abine, and disease state at transplantation) and transplantation-related
variables (time from diagnosis to transplantation, donor age, donor-
recipient gender and cytomegalovirus serology, year of transplantation,
and GVHD prophylaxis). None of the variables with > 20% missing infor-
mation were included in the model.
RESULTS AND DISCUSSION
Demographic features of the cohorts are shown in Table 1.
Median ages were 48 and 49 years with a male predomi-
nance, in both groups. Most subjects had early Rai stage at
diagnosis (66% versus 54%) without B symptoms (60% versus
63%). Both cohorts had a median of 3 prior therapies and
most were resistant to their last therapy (75% versus 77%),
did not have a splenectomy (91% for both), and a similar
proportion had failed ﬂudarabine (45% versus 50%, respec-
tively). The proportions of subjects in complete or partial
remission before transplantation were similar: 46% and 44%.
Most subjects in the TBI cohort received cyclophospha-
mide. Ninety-six percent of subjects in the CTcohort received
a busulfan-based regimen, which was given orally in 48%,
intravenously in 28%, and not reported in 24%. Fifty percent
of TBI subjects received blood cell grafts versus 72% of CT
subjects (P ¼ .006). Fifteen percent of subjects in the CT
cohort received antithymocyte globulin before trans-
plantation versus none in the TBI cohort (P < .001).
One hundred day cumulative incidences of neutrophil
recovery in the TBI and CT cohorts were similar, (98% [95%
conﬁdence interval (CI), 95% to 100%] and 96% [95% CI, 90% to
100%]; P ¼ .45). Corresponding 100-day cumulative in-
cidences of platelet recovery were 82% (95% CI, 74% to 88%)
and 83% (95% CI, 72% to 91%); P ¼ .86. Five-year TRM rateswere 48% (95% CI, 39% to 57%) versus 50% (95% CI, 36% to
64%); P ¼ NS. One hundrededay rates of  grade 2 acute
GVHDwere similar: 49% (95% CI, 41% to 58%) versus 43% (95%
CI, 30% to 57%); P ¼ .47. One-year incidence of chronic GVHD
was 45% (95%, CI 36% to 54%) versus 37% (95% CI, 24% to 51%);
P ¼ .14. Five-year relapse rates were 17% (95% CI, 11% to 25%)
versus 22% (95% CI, 11% to 35%); P ¼ NS. Five-year PFS was
34% (95% CI, 26% to 43%) versus 28% (95% CI, 15% to 42%); P ¼
NS. Five-year OS was 42% (95% CI, 33% to 51%) versus 33%
(95% CI, 19% to 48%); P ¼ NS (see Figure 1).
The proportion of deaths in both cohorts was similar at
61% and 65% (Table 2). The single most frequent cause of
death was relapse. However, the pattern of other causes of
deaths differed between the 2 groups: the TBI cohort had
more deaths from infection, acute respiratory distress syn-
drome, and GVHD, whereas the CT cohort had more deaths
from organ failure, hemorrhage, and liver veno-occlusive
disease. No factor tested signiﬁcantly affected reported out-
comes, including having failed ﬂudarabine (Table 3). New
cancers occurred in both cohorts (TBI ¼ 11 versus CT ¼ 3).
Rates were not signiﬁcantly different, but this conclusion is
limited by the small cohorts. A total of 4 deaths from new
cancers occurred only in the TBI cohort: acute lymphoblastic
leukemia (n ¼ 1), breast cancer (n ¼ 1), gastrointestinal
cancer (n ¼ 1), and other cancer (n ¼ 1).
In summary, we found no signiﬁcant differences in out-
comes after myeloablative HLA-identical sibling trans-
plantations for CLL using TBI-containing or CT conditioning
Table 3
Multivariate Analysis
Outcomes RR P Value 95% CI n
Neutrophil recovery
TBI 1 123
CT .64 .63 .10-3.93 53
Acute GVHD  grade 2
TBI 1 123
CT .96 .86 .60-1.54 52
Chronic GVHD
TBI 1 112
CT .88 .65 .52-1.51 52
Relapse
TBI 1 123
CT 1.49 .30 .70-3.18 53
TRM
TBI 1 123
CT 1.28 .30 .80-2.05 53
PFS
TBI 1 123
CT 1.33 .16 .90-1.99 53
Survival
TBI 1 126
CT 1.34 .161 .89-2.02 54
RR indicates relative risk; CI, conﬁdence interval; TBI, total body irradiation;
CT, chemotherapy; GVHD, graft-versus-host disease; TRM, treatment-
related mortality; PFS, progression-free survival.
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small sample size, especially in the CT cohort, with resultant
low power to detect possible differences. A larger observa-
tional data set to address this question is unlikely to evolve
because of a shift to less intensive conditioning and because
no randomized study is likely to be done.
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